Andrew D. Goodman, MD, FAAN, FANA, is Professor of Neurology, Chief of the Neuroimmunology Division, and Director of the Multiple Sclerosis Center at the University of Rochester.
Dr. Goodman’s interests include clinical and experimental therapeutics research. He has been the lead investigator (or a member of the steering committee) for various national and international clinical trials of new therapies for multiple sclerosis including natalizumab and dalfampridine. He is currently a member of the protocol committee and site-PI for the “SPRINT MS” study of ibudilast in secondary progressive MS sponsored by NeuroNext (NIH) and NMSS. Dr. Goodman is a co-PI of a project funded by the New York State Stem Cell program (NYSTEM) that plans to perform a phase 1, first in man study testing the safety of transplanting oligodendrocyte precursor cells into the cerebral white matter of patients with progressive multiple sclerosis.
He is a past chair of the MS section of the AAN. He has also served on the International Advisory Committee on Clinical Trials in MS, the ACTRIMS Board of Directors, and the Executive Committee of the NMSS Clinical Advisory Committee.
Dr. Goodman is a graduate of Rutgers College and the Rutgers New Jersey Medical School; he did residency training in internal medicine and neurology at Mt. Sinai Medical Center in New York City. He completed a research fellowship in the Neuroimmunology Branch at the National Institutes of Health, Bethesda, Maryland.